AstraZeneca Pharma India Limited — Q1 FY26 earnings call

Call held 14 Aug 2025

Management summary

AstraZeneca India delivered a robust performance in FY25 and started Q1 FY26 with 34% revenue growth, primarily fueled by its dominant Oncology segment. While headline EPS was pressured by a ₹90 crore one-off charge related to plant closure and strategic restructuring, underlying profitability grew by 25%. Management is pivoting heavily toward a 'specialist' model, prioritizing Oncology, Rare Diseases, and Biopharmaceuticals while maintaining high inventory levels to ensure product availability for aggressive growth targets.

Highlights

  • Revenue from operations for FY24-25 reached ₹1,716 crore, representing a 32% YoY growth.

  • Profit before exceptional items and tax stood at ₹253 crore, reflecting a 25% growth.

  • Oncology portfolio now contributes nearly 70% of total revenue, driven by brands like Enhertu and Tagrisso.

  • Q1 FY26 revenue growth reported at 34% YoY, maintaining strong momentum.

  • Earnings Per Share (EPS) for the year was ₹46.3, impacted by a ₹90 crore one-off strategic charge.

  • Declared a dividend of ₹32 per share for the financial year 2024-2025.

  • Inventory levels increased significantly to ₹5,485 (unit implied as lakhs/crores based on context) to support growth plans.

  • Global 2030 ambition set to reach $80 billion in revenue with 20 new medicine launches.

Key financials

2 periods

Headline

  • Revenue
    ₹1,716 Cr
    YoY +32%
  • Profit Before Exceptional Items
    ₹253 Cr
    YoY +25%
  • EPS
    ₹46.3
    YoY -27%
  • Dividend
    ₹32
    YoY 0%

Q1 FY26

  • Revenue Growth
    34%
    YoY +34%

What they filed

Q1 FY27: revenue up 29.8%, net profit down 32.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue408 440 480 526 559 +37%612 +39%579 +21%683 +30%
EBITDA53 77 86 81 75 +42%45 −42%61 −29%49 −40%
Net profit38 31 58 56 54 +42%33 +6%45 −22%38 −32%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Oncology
    70% Revenue Share49% Revenue Growth
  • Biopharmaceuticals
    8% Revenue Growth
  • Rare Disease
    15.5% Global Revenue Share

Guidance & targets

Volume

  • New Medicine Launches Volume · by 2030 · High confidence 20
    By 2030, we will deliver 20 new medicines

    — Praveen Rao Akkinepally, Managing Director

Other

  • Carbon Footprint Other · by 2030 · Medium confidence Carbon Negative
    and be carbon negative.

    — Praveen Rao Akkinepally, Managing Director

Market context

  • Global Total Revenue Revenue · by 2030 · High confidence $80 billion
    By 2030, we will deliver 20 new medicines, globally be an $80 billion company, and be carbon negative.

    — Praveen Rao Akkinepally, Managing Director

Risks & concerns

  • Revenue Concentration in Oncology

    medium

    Oncology contributes ~70% of revenue; analysts expressed concern about reliance on a single segment.

    Analyst acknowledged

  • Inventory Carrying Costs

    medium

    Inventory levels more than doubled (from 2,278 to 5,485) to support growth, tying up working capital.

    Both defended

  • Rare Disease Market Maturity

    medium

    Rare disease segment is in 'early days' in India and requires significant investment in diagnosis awareness.

    Management acknowledged

  • One-off Strategic Costs

    low

    ₹90 crore charge for plant closure and restructuring impacted FY25 PAT.

    Management acknowledged

Areas of evasion (1)

  • Specific R&D expenditure as a percentage of India-specific revenue was not disclosed, cited as 'integrated' with global operations.

Q&A highlights

2 direct
EPS Decline and One-off Items Direct
Because of the strategic decisions of the Company, we had to book some one off items of about Rs. 90 crores plus. And considering that our EPS after the exceptional item has actually reduced versus last year.

Clarifies that the apparent drop in EPS was due to a non-recurring strategic charge (plant closure) rather than a decline in core business health.

Asked by H. S. Patel

Oncology Concentration and Diversification Partial
Oncology has driven quite a bit of growth over the last year, but we are very much committed to all of the therapeutic areas... I expect that [Rare Disease] will be an ongoing effort. It will take several years.

Highlights the risk of 70%+ revenue concentration in Oncology and management's long-term plan to diversify into Rare Diseases.

Asked by Satish Bhatt

High Inventory Levels Direct
The inventory level has gone up and it has grown up in anticipation of the growth plans that we have... entirely on making sure that product is available as and when patients really require it.

Explains the significant jump in inventory as a proactive move to support aggressive sales targets rather than a sign of slow-moving stock.

Asked by H. S. Patel

2 min read 5 chapters

Detailed narrative

Oncology Dominance Fuels Growth

The Oncology segment has become the primary engine for AstraZeneca India, now accounting for nearly 70% of total revenue. Key brands like Enhertu, Tagrisso, and Imfinzi are driving this, with the Oncology portfolio growing at 49% YoY. Tagrisso remains the #1 lung cancer brand in India, while Enhertu surpassed ₹200 crore in revenue within just 12 months of its launch.

Strategic Restructuring and One-off Impacts

The company reported a ₹90 crore exceptional charge in FY25, which management attributed to strategic decisions including the closure of a manufacturing plant. This one-off item caused a reported decline in EPS from ₹64 to ₹46.3, despite a 25% increase in underlying profit before exceptional items. Management emphasized that this move aligns with their shift toward a more specialized, high-innovation product mix.

Aggressive Inventory Build-up

Inventory levels saw a sharp increase, rising from ₹2,278 to ₹5,485. Management defended this build-up as a necessary step to ensure product availability for their aggressive growth trajectory, particularly for newly launched specialty medicines. They noted that Q1 FY26 has already seen a 34% revenue growth, justifying the need for higher stock levels to prevent supply chain disruptions.

Rare Disease: The Next Frontier

AstraZeneca is laying the foundation for a Rare Disease business in India, recently launching Koselugo and Soliris. While currently in the 'early days,' management expects this segment to eventually mirror the global mix, where Rare Diseases contribute 15-16% of total revenue. The strategy involves heavy investment in diagnostic awareness and policy engagement to address unmet needs in conditions like PNH and aHUS.

2030 Global and Local Synergy

The India strategy is tightly aligned with AstraZeneca's global 'Bold Ambition' to become an $80 billion company by 2030. This involves launching 20 new medicines globally, many of which are slated for the Indian market. Management is focusing on 'specialist' disease areas rather than broad-market generics, leveraging policy reforms like patent amendments and PMP guidelines to accelerate innovation access.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls